S1P1 agonist study in multiple sclerosis

• Research type

  Research Study

• Full title

  Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis

• IRAS ID

  16014

• Contact name

  David Bates

• Contact email

  david.bates@newcastle.ac.uk

• Sponsor organisation

  Actelion Pharmaceuticals Ltd

• Eudract number

  2008-006786-92

• ISRCTN Number

  n/a

• Research summary

  Researcher request not to publish

• REC name

  North East - Tyne & Wear South Research Ethics Committee

• REC reference

  09/H0904/29

• Date of REC Opinion

  17 Jul 2009

• REC opinion

  Further Information Favourable Opinion